Get the Stockscreener App
0.657
1.94%
-0.013
After Hours:
.68
0.023
+3.50%
Xilio Therapeutics Inc Stock (XLO) Latest News
RNA Based Therapeutic Market Size Expected to Reach USD 40.81 Bn by 2034 - GlobeNewswire Inc.
Allarity Therapeutics (NASDAQ:ALLR) and Xilio Therapeutics (NASDAQ:XLO) Financial Contrast - Defense World
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 44.5% in January - Defense World
Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Increase in Short Interest - Defense World
Xilio shares tumble after mixed vilastobart data - The Pharma Letter
Vilastobart set apart? Xilio phase II combo performs in CRC - BioWorld Online
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - BioSpace
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - The Manila Times
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer - Marketscreener.com
Xilio Therapeutics Advances with Phase 2 Trial Data - TipRanks
Xilio Therapeutics Announces Initial Phase 2 Data for - GlobeNewswire
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated - The Bakersfield Californian
Xilio Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - Marketscreener.com
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Xilio Therapeutics Awards 60,000-Share Stock Option Grant to New Employee at $0.955 - StockTitan
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Rises By 221.7% - Defense World
Geode Capital Management LLC Grows Position in Xilio Therapeutics, Inc. (NASDAQ:XLO) - Defense World
Xilio Therapeutics Inc [XLO] stock for 6,841 USD was sold by Frankenfield Christopher James - Knox Daily
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 31.9% in December - Defense World
Xilio Therapeutics Enters into Additional Private Placement with Gilead; Issues Securities at $25 Million Aggregate Investment - Defense World
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock - Investing.com India
Gilead Sciences acquires $1.83 million in Xilio Therapeutics stock By Investing.com - Investing.com Australia
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated - The Bakersfield Californian
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI - GlobeNewswire
Xilio Therapeutics Hires Caroline Hensley as Chief Legal Officer - Bloomberg Law
Biotech Biz Xilio Therapeutics Appoints Chief Legal Officer - Law360
Xilio Therapeutics, Inc. Appoints Caroline Hensley as chief legal officer -December 16, 2024 at 07:30 am EST - Marketscreener.com
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer - The Bakersfield Californian
Xilio Therapeutics Strengthens Leadership Team, Appoints Seres Therapeutics Veteran as Chief Legal Officer - StockTitan
Short Interest in Xilio Therapeutics, Inc. (NASDAQ:XLO) Increases By 317.4% - Defense World
After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - MSN
Here's Why We're Not Too Worried About Xilio Therapeutics' (NASDAQ:XLO) Cash Burn Situation - Yahoo Finance
Xilio Therapeutics Issues New Employee Stock Options Under Nasdaq Inducement Plan - StockTitan
Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Down 89.4% in November - Defense World
Raymond James Cuts Xilio Therapeutics (NASDAQ:XLO) Price Target to $4.00 - Defense World
Xilio to present new cancer treatment data at SITC By Investing.com - Investing.com Australia
Xilio Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Xilio Therapeutics Inc. (XLO) Quarterly 10-Q Report - Quartzy
Xilio to present new cancer treatment data at SITC - Investing.com
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results - citybiz
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors - GlobeNewswire
Xilio's Cancer Drug Shows Promise: Liver Metastasis Resolution in Clinical Trial | XLO Stock News - StockTitan
2.27%
5.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):